Classifier of cross talk genes predicts the prognosis of hepatocellular carcinoma

Zhai,Xiaofeng; Xue,Qingfeng; Liu,Qun; Guo,Yuyu; Chen,Zhe

doi:10.3892/mmr.2017.7003

Classifier of cross talk genes predicts the prognosis of hepatocellular carcinoma

Authors:
- Xiaofeng Zhai
- Qingfeng Xue
- Qun Liu
- Yuyu Guo
- Zhe Chen
View Affiliations

Affiliations: Department of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, P.R. China, Department of Anesthesiology, Chinese People's Liberation Army 264 Hospital, Taiyuan, Shanxi 030001, P.R. China
Published online on: July 15, 2017 https://doi.org/10.3892/mmr.2017.7003
Pages: 3253-3261
Copyright: © Zhai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to establish a prediction model for hepatocellular carcinoma (HCC) based on the cross talk genes from important biological pathways involved in HCC. Differentially expressed genes (DEGs) for HCC were identified from mRNA profiles of GSE36376, which were mapped to protein‑protein interaction (PPI) networks from BioGrid and the human protein reference database. Then critical genes based on the deviation score and the degree of node were selected from the novel PPI network. Cross talk genes were screened from the network established based on the associations of gene‑gene, gene‑pathway and pathway‑pathway. A classifier based on specific cross talk genes was constructed for prediction of HCC using the random forest algorithm. Finally, the diagnostic performance of this prediction model was verified by predicting survival time of patients with HCC from the genome cancer atlas (TCGA) and other independent gene expression omnibus (GEO) databases. From the novel PPI network, a total of 200 critical genes were screened out and they were significantly enriched in 23 pathways, which have been reported to be significantly associated with the development of HCC. Based on these identified pathways, cross talk genes were identified including AKT1, SOS1, EGF, MYC, IGF1, ERBB2, CDKN1B, SHC2, VEGFA and INS. The prediction model has a relative average classification accuracy of 0.94 for HCC, which has a stable predicting efficacy for survival time of HCC patients validated in the TCGA database and two other independent GEO datasets. In conclusion, a total of 39 cross talk genes in HCC were identified and a classifier based on the cross talk genes was constructed, which indicates a high prognosis prediction efficacy in several independent datasets. The results provide a novel perspective to develop a multiple gene diagnostic tool for HCC prognosis, which also provided potential biomarkers or therapeutic targets for HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
3	Marrero JA, Kudo M and Bronowicki JP: The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 15:(Suppl 4). S23–S33. 2010. View Article : Google Scholar
4	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
5	Li D and Satomura S: Biomarkers for hepatocellular carcinoma (HCC): An update. Adv Exp Med Biol. 867:179–193. 2015. View Article : Google Scholar : PubMed/NCBI
6	Reuter JA, Spacek DV and Snyder MP: High-throughput sequencing technologies. Mol Cell. 58:586–597. 2015. View Article : Google Scholar : PubMed/NCBI
7	Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J and Odom DT: ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions. Methods. 48:240–248. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mathew R, Karantza-Wadsworth V and White E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007. View Article : Google Scholar : PubMed/NCBI
9	Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, et al: Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol. 166:1205–1216. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:436–440. 1994. View Article : Google Scholar : PubMed/NCBI
11	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
12	Arwert EN, Hoste E and Watt FM: Epithelial stem cells, wound healing and cancer. Nat Rev Cancer. 12:170–180. 2012. View Article : Google Scholar : PubMed/NCBI
13	Berkeley C: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article32004.PubMed/NCBI
14	Aoki-Kinoshita K, Kanehisa M and Bergman N: Comparative genomics. Journal. 2007.
15	Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
16	Köhn HF and Hubert LJ: Hierarchical cluster analysis. Wiley StatsRef: Statistics Reference Online. 2006.
17	Liaw A and Wiener M: Classification and regression by randomForest. R News. 2:18–22. 2002.
18	Vazquez A, Flammini A, Maritan A and Vespignani A: Global protein function prediction from protein-protein interaction networks. Nat Biotechnol. 21:697–700. 2003. View Article : Google Scholar : PubMed/NCBI
19	Colcombet J and Hirt H: Arabidopsis MAPKs: A complex signalling network involved in multiple biological processes. Biochem J. 413:217–226. 2008. View Article : Google Scholar : PubMed/NCBI
20	Stuart JM, Segal E, Koller D and Kim SK: A gene-coexpression network for global discovery of conserved genetic modules. Science. 302:249–255. 2003. View Article : Google Scholar : PubMed/NCBI
21	Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA and Afdhal NH: Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 14:470–477. 2008. View Article : Google Scholar : PubMed/NCBI
22	Lodish H, Berk A, Kaiser CA, Krieger M, Bretscher A, Ploegh H and Amon A: Molecular Cell Biology. 7th. W H Freeman and Company; New York: 2012
23	Przulj N, Wigle DA and Jurisica I: Functional topology in a network of protein interactions. Bioinformatics. 20:340–348. 2004. View Article : Google Scholar : PubMed/NCBI
24	Fabregat I: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol. 15:513–520. 2009. View Article : Google Scholar : PubMed/NCBI
25	Nakanishi K, Sakamoto M, Yamasaki S, Todo S and Hirohashi S: Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 103:307–312. 2005. View Article : Google Scholar : PubMed/NCBI
26	Borlak J, Meier T, Halter R, Spanel R and Spanel-Borowski K: Epidermal growth factor-induced hepatocellular carcinoma: Gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene. 24:1809–1819. 2005. View Article : Google Scholar : PubMed/NCBI
27	Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M and Scherübl H: Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol. 41:1008–1016. 2004. View Article : Google Scholar : PubMed/NCBI
28	Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 431:1112–1117. 2004. View Article : Google Scholar : PubMed/NCBI
29	Marrero JA and Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology. 127:(5 Suppl 1). S113–S119. 2004. View Article : Google Scholar : PubMed/NCBI
30	Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 52:550–559. 2010. View Article : Google Scholar : PubMed/NCBI
31	Bekaii-Saab T, Williams N, Plass C, Calero MV and Eng C: A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer. 6:2782006. View Article : Google Scholar : PubMed/NCBI
32	Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L and Negrini M: MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
33	Whittaker S, Marais R and Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 29:4989–5005. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
35	Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I and Philip PA: Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature. Cancer. 115:4895–4906. 2009. View Article : Google Scholar : PubMed/NCBI
36	Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C, Odenthal M, Schulze F, et al: The toll-like receptor 2 (TLR2)-196 to −174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer. 130:1470–1475. 2012. View Article : Google Scholar : PubMed/NCBI
37	Timofeeva OA, Zhang X, Ressom HW, Varghese RS, Kallakury BV, Wang K, Ji Y, Cheema A, Jung M, Brown ML, et al: Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol. 35:751–760. 2009.PubMed/NCBI
38	De S, Dermawan JK and Stark GR: EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci USA. 111:11721–11726. 2014. View Article : Google Scholar : PubMed/NCBI